Researchers found that cannabinoid-based medications (CBM), specifically a combination of THC and CBD, may not significantly reduce agitation in people with severe dementia, but they could help lower the need for additional psychotropic medications. In a study conducted in five long-term care facilities in Geneva, Switzerland, 25 patients aged around 83 participated in a trial where they received either the cannabinoid treatment or a placebo over two 8-week periods.

This finding is important for anyone looking to support loved ones with dementia. While the study did not show a direct benefit in reducing agitation, the reduction in the use of as-needed psychotropic medications suggests that CBM could be a safer alternative for managing some behavioral symptoms. This could mean fewer side effects and a better quality of life for individuals dealing with severe dementia.

The evidence comes from a multicenter, randomized, double-blind, placebo-controlled trial, which is a strong research design. However, it involved a small group of participants, and the results indicate that while CBM may not be a standalone solution for agitation, it could still play a role in a broader treatment plan. The researchers concluded that more extensive studies are necessary to fully understand the potential benefits and limitations of cannabinoid-based therapies for dementia-related symptoms.

If you are considering cannabinoid treatments for dementia, it’s essential to consult with a healthcare professional who can provide guidance tailored to individual circumstances and needs.

For more details, see the original study published in Age and Ageing.